ESPR Esperion Therapeutics Inc.

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:30 a.m. ET.

The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics

At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit and and follow us on X at .

Esperion Contact Information:

Investors:

Alina Venezia



(734) 887-3903

Media:

Tiffany Aldrich



(616) 443-8438



EN
04/11/2024

Underlying

ESPREsperion Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Esperion Therapeutics Inc.

 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such in...

November 8, 2024 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Reports Third Quarter 2024 Financial Results and Provides a B...

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update – Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New to Brand Prescriptions Grew 18% from Second Quarter – – October 2024 Total Retail Prescription Equivalents Increased 17% and New to Brand Prescriptions Grew 20% Compared to First Four Weeks of Q3 2024 – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Nov. 07, 2024 (GLOBE NEWSWIRE) --...

November 7, 2024 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Participate in Upcoming Jefferies London Healthcare Confer...

Esperion to Participate in Upcoming Jefferies London Healthcare Conference ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:30 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion Therap...

November 4, 2024 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Announces a Featured Presentation in the Late Breaker/Feature...

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions ANN ARBOR, Mich., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that one featured presentation in the Late Breaker/Featured Science track and three poster presentations have been accepted for the AHA Scientific Sessions 2024 in Chicago, IL, November 16-18, 2024. Featured ScienceBempedoic Acid and Limb Outcomes in Statin-Intolerant Patients with Peripheral Artery Disease: ...

October 31, 2024 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Report Third Quarter 2024 Financial Results on November 7

Esperion to Report Third Quarter 2024 Financial Results on November 7 ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and media section of the Esp...

October 24, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch